Search results
Results from the WOW.Com Content Network
The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity -- the first medication ...
The FDA said Zepbound’s approval for moderate to severe obstructive sleep apnea in adults with obesity is based on two placebo-controlled studies of 469 adults without type 2 diabetes.
The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug Administration Dec. 20 press release.
Tirzepatide was approved for treatment of diabetes in the U.S. in May 2022, [9] [13] in the European Union in September 2022, [11] in Canada in November 2022, [19] and in Australia in December 2022. [2] The U.S. Food and Drug Administration (FDA) considers it a first-in-class medication. [20] [21] The FDA approved it for weight loss in November ...
The regulator approved the drug for moderate to severe obstructive sleep apnea in adults with obesity, the company said. The approval opens up a wide market of patients for Lilly at a time when ...
The United States Food and Drug Administration and the European Medicines Agency have approved weight loss medications for adults with either a body-mass index (BMI) of at least 30, or a body-mass index of at least 27 with at least one weight-related comorbidity. This patient population is considered to have sufficiently high baseline health ...
The Food and Drug Administration (FDA) approved a weight-loss drug to help sleep apnea, becoming the first drug to treat the disorder affecting millions of Americans. On Friday, the federal agency ...
Earlier studies have shown that when people lose weight, it can help improve their sleep apnea. The US Food and Drug Administration approved Zepbound to treat obesity in November. The drug ...